{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:23Z","timestamp":1787004863816,"version":"build-2736575974"},"reference-count":120,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The endocannabinoid system shows promise as a novel target for treating\n                    psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid,\n                    has been investigated in several psychiatric conditions, with diverse effects\n                    and an excellent safety profile compared to standard treatments. Even though the\n                    body of evidence from randomised clinical trials is growing, it remains\n                    relatively limited in most indications. This review comprises a comprehensive\n                    literature search to identify clinical studies on the effects of CBD in\n                    psychiatric conditions. The literature search included case studies, case\n                    reports, observational studies, and RCTs published in English before July 27,\n                    2023, excluding studies involving nabiximols or cannabis extracts containing CBD\n                    and \u22069-tetrahydrocannabinol. Completed studies were\n                    considered, and all authors independently assessed relevant publications.<\/jats:p>\n                  <jats:p>Of the 150 articles identified, 54 publications were included, covering the\n                    effects of CBD on healthy subjects and various psychiatric conditions, such as\n                    schizophrenia, substance use disorders (SUDs), anxiety, post-traumatic stress\n                    disorder (PTSD), and autism spectrum disorders. No clinical studies have been\n                    published for other potential indications, such as alcohol use disorder,\n                    borderline personality disorder, depression, dementia, and\n                    attention-deficit\/hyperactivity disorder. This critical review\n                    highlights that CBD can potentially ameliorate certain psychiatric conditions,\n                    including schizophrenia, SUDs, and PTSD. However, more controlled studies and\n                    clinical trials, particularly investigating the mid- to long-term use of CBD,\n                    are required to conclusively establish its efficacy and safety in treating these\n                    conditions. The complex effects of CBD on neural activity patterns, likely by\n                    impacting the endocannabinoid system, warrant further research to reveal its\n                    therapeutic potential in psychiatry.<\/jats:p>","DOI":"10.1055\/a-2228-6118","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T19:12:45Z","timestamp":1706123565000},"page":"115-132","source":"Crossref","is-referenced-by-count":18,"title":["Cannabidiol and its Potential Evidence-Based Psychiatric Benefits\n                    \u2013 A Critical Review"],"prefix":"10.1055","volume":"57","author":[{"given":"Inga","family":"Dammann","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental\n                    Health, Medical Faculty Mannheim, Heidelberg University, Mannheim,\n                    Germany"},{"name":"Endosane Pharmaceuticals GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrin","family":"Rohleder","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental\n                    Health, Medical Faculty Mannheim, Heidelberg University, Mannheim,\n                    Germany"},{"name":"Endosane Pharmaceuticals GmbH, Berlin, Germany"},{"name":"Brain and Mind Centre, Faculty of Medicine and Health, The University\n                    of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Markus","family":"Leweke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental\n                    Health, Medical Faculty Mannheim, Heidelberg University, Mannheim,\n                    Germany"},{"name":"Brain and Mind Centre, Faculty of Medicine and Health, The University\n                    of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"101675","DOI":"10.1016\/j.eclinm.2022.101675","article-title":"Quantifying the global burden of mental disorders and their economic value","volume":"54","author":"D Arias","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s2215-0366(21)00395-3","article-title":"2019 Mental Disorders Collaborators. Global, regional, and national burden of 12\n                    mental disorders in 204 countries and territories, 1990\u20132019: A\n                    systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"GBD","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.2174\/138161212802884744","article-title":"The endocannabinoid system and schizophrenia: Integration of evidence","volume":"18","author":"E Zamberletti","year":"2012","journal-title":"Curr Pharm Des"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bpsc.2020.07.016","article-title":"Review of the endocannabinoid system","volume":"6","author":"H-C Lu","year":"2020","journal-title":"Biol Psychiatry Cognitive Neurosci Neuroimaging"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1\n                    receptor","volume":"172","author":"R B Laprairie","year":"2015","journal-title":"Brit J Pharmacol"},{"key":"ref6","first-page":"105","article-title":"Pharmakologie von cannabis und cannabinoiden","volume":"27","author":"C Rohleder","year":"2020","journal-title":"Psychopharmakologie"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet\n                    syndrome","volume":"114","author":"J S Kaplan","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.yebeh.2017.07.014","article-title":"Anticonvulsant effect of cannabidiol in the pentylenetetrazole model:\n                    Pharmacological mechanisms, electroencephalographic profile, and brain cytokine\n                    levels","volume":"75","author":"L R Vilela","year":"2017","journal-title":"Epilepsy Behav"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/sj.bjp.0707423","article-title":"Cannabinoids go nuclear: Evidence for activation of peroxisome\n                    proliferator-activated receptors","volume":"152","author":"S E O\u2019Sullivan","year":"2007","journal-title":"Brit J Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of\n                    schizophrenia","volume":"2","author":"F M Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on\n                    vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of\n                    anandamide","volume":"134","author":"T Bisogno","year":"2001","journal-title":"Brit J Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.m114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for\n                        \u03949-tetrahydrocannabinol (THC) and cannabidiol\n                    (CBD)*","volume":"290","author":"M W Elmes","year":"2015","journal-title":"J Biol Chem"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"E B Russo","year":"2005","journal-title":"Neurochem Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","article-title":"Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and\n                    nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic\n                    autoreceptors in the dorsal raphe nucleus","volume":"165","author":"E M Rock","year":"2012","journal-title":"Br J Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbr.2016.04.042","article-title":"Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein\n                    expression in the dorsolateral striatum via 5-HT1A receptors in mice","volume":"309","author":"A B Sonego","year":"2016","journal-title":"Behav Brain Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00213-010-2036-z","article-title":"The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the\n                    stria terminalis are mediated by 5-HT1A receptors","volume":"213","author":"F V Gomes","year":"2011","journal-title":"Psychopharmacology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40263-018-0539-z","article-title":"Role of the endocannabinoid system in the pathophysiology of schizophrenia:\n                    Implications for pharmacological intervention","volume":"32","author":"F M Leweke","year":"2018","journal-title":"CNS Drugs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.31887\/dcns.2020.22.3\/mcrocq","article-title":"History of cannabis and the endocannabinoid system","volume":"22","author":"M-A Crocq","year":"2020","journal-title":"Dialogues Clin Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic\n                    reviews","volume":"372","author":"M J Page","year":"2021","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0269881108096521","article-title":"Cannabidiol was ineffective for manic episode of bipolar affective disorder","volume":"24","author":"A Zuardi","year":"2010","journal-title":"J Psychopharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1212\/01.con.0000466662.89908.e7","article-title":"Psychosis","volume":"21","author":"D B Arciniegas","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general\n                    population","volume":"64","author":"J Per\u00e4l\u00e4","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5498\/wjp.v11.i7.277","article-title":"Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug\n                    targets","volume":"11","author":"M \u013dupt\u00e1k","year":"2021","journal-title":"World J Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","article-title":"Elevated endogenous cannabinoids in schizophrenia","volume":"10","author":"F M Leweke","year":"1999","journal-title":"NeuroReport"},{"key":"ref25","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"A W Zuardi","year":"1995","journal-title":"J Clin psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia","volume":"20","author":"A W Zuardi","year":"2006","journal-title":"J Psychopharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease","volume":"23","author":"A Zuardi","year":"2009","journal-title":"J Psychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/0004867418815982","article-title":"Remission of severe, treatment-resistant schizophrenia following adjunctive\n                    cannabidiol","volume":"53","author":"C Makiol","year":"2019","journal-title":"Aust N Zealand J Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"614811","DOI":"10.3389\/fphar.2021.614811","article-title":"Cannabidiol and amisulpride improve cognition in acute schizophrenia in an\n                    explorative, double-blind, active-controlled, randomized clinical trial","volume":"12","author":"F M Leweke","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter\n                    randomized controlled trial","volume":"175","author":"P McGuire","year":"2018","journal-title":"Am J Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with\n                    chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"D L Boggs","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jpsychires.2023.05.019","article-title":"The impact of cannabidiol treatment on resting state functional connectivity,\n                    prefrontal metabolite levels and reward processing in recent-onset patients with\n                    a psychotic disorder","volume":"163","author":"R van Boxel","year":"2023","journal-title":"J Psychiatr Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/jamapsychiatry.2018.2165","article-title":"Prediction models of functional outcomes for individuals in the clinical\n                    high-risk state for psychosis or with recent-onset depression: A multimodal,\n                    multisite machine learning analysis","volume":"75","author":"N Koutsouleris","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamapsychiatry.2013.1909","article-title":"Prediction of functional outcome in individuals at clinical high risk for\n                    psychosis","volume":"70","author":"R E Carri\u00f3n","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000365221","article-title":"Attenuated psychosis syndrome: Need for debate on a new disorder","volume":"47","author":"W T Carpenter","year":"2014","journal-title":"Psychopathology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1088459","DOI":"10.3389\/fpsyt.2023.1088459","article-title":"Cannabidiol enhances cerebral glucose utilization and ameliorates\n                    psychopathology and cognition: A case report in a clinically high-risk mental\n                    state","volume":"14","author":"D Koethe","year":"2023","journal-title":"Front Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","article-title":"Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in\n                    people at clinical high risk of psychosis: A randomized clinical trial","volume":"75","author":"S Bhattacharyya","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","article-title":"Effects of short-term cannabidiol treatment on response to social stress in\n                    subjects at clinical high risk of developing psychosis","volume":"237","author":"E Appiah-Kusi","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00406-021-01318-z","article-title":"Altered relationship between cortisol response to social stress and\n                    mediotemporal function during fear processing in people at clinical high risk\n                    for psychosis: A preliminary report","volume":"272","author":"C Davies","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref40","first-page":"1","article-title":"Die Bedeutung der Rauschgiftversuche fuer die Klinik","volume":"28","author":"K Behringer","year":"1932","journal-title":"Archiv fuer Neurologie"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00213-009-1591-7","article-title":"The endocannabinoid system as a target for modelling psychosis","volume":"206","author":"D Koethe","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.biopsych.2016.02.005","article-title":"Cannabis and psychosis: What degree of proof do we require?","volume":"79","author":"R M Murray","year":"2016","journal-title":"Biol Psychiatry"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.biopsych.2008.05.011","article-title":"Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: Effects during\n                    response inhibition","volume":"64","author":"S J Borgwardt","year":"2008","journal-title":"Biol Psychiatry"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain\n                    function and psychopathology","volume":"35","author":"S Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/npp.2011.17","article-title":"Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and\n                    cannabidiol: An FMRI study","volume":"36","author":"T T Winton-Brown","year":"2011","journal-title":"Neuropsychopharmacol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.euroneuro.2018.04.004","article-title":"Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters\n                    fronto-striatal resting-state connectivity","volume":"28","author":"O Grimm","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41398-019-0534-2","article-title":"Cannabidiol attenuates insular dysfunction during motivational salience\n                    processing in subjects at clinical high risk for psychosis","volume":"9","author":"R Wilson","year":"2019","journal-title":"Transl Psychiatry"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41398-020-0862-2","article-title":"A single dose of cannabidiol modulates medial temporal and striatal function\n                    during fear processing in people at clinical high risk for psychosis","volume":"10","author":"C Davies","year":"2020","journal-title":"Transl Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1017\/s0033291719003519","article-title":"Normalization of mediotemporal and prefrontal activity, and\n                    mediotemporal-striatal connectivity, may underlie antipsychotic effects of\n                    cannabidiol in psychosis","volume":"51","author":"A O\u2019Neill","year":"2021","journal-title":"Psychol Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s0740-5472(00)00094-5","article-title":"Treating substance abuse in the context of severe and persistent mental illness\n                    Clinicians\u2019 perspectives","volume":"19","author":"K B Carey","year":"2000","journal-title":"J Subst Abus Treat"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bcp.2018.09.013","article-title":"Role of the endocannabinoid system in drug addiction","volume":"157","author":"J Manzanares","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/can.2019.0024","article-title":"Oral cannabidiol does not convert to \u03948-THC or\n                        \u03949-THC in humans: A pharmacokinetic study in healthy\n                    subjects","volume":"5","author":"JA S Crippa","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent\n                    marijuana smokers","volume":"172","author":"S Babalonis","year":"2017","journal-title":"Drug Alcohol Depen"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1177\/0269881120944148","article-title":"The acute effects of cannabidiol on the neural correlates of reward anticipation\n                    and feedback in healthy volunteers","volume":"34","author":"W Lawn","year":"2020","journal-title":"J Psychopharmacol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/jcpt.12018","article-title":"Cannabidiol for the treatment of cannabis withdrawal syndrome: A case\n                    report","volume":"38","author":"JA S Crippa","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"ref56","first-page":"31","article-title":"Cannabidiol oil for decreasing addictive use of marijuana: A case report","volume":"14","author":"S Shannon","year":"2015","journal-title":"Integr Med (Encinitas, Calif)"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/s2215-0366(20)30290-x","article-title":"Cannabidiol for the treatment of cannabis use disorder: A phase 2a,\n                    double-blind, placebo-controlled, randomised, adaptive Bayesian trial","volume":"7","author":"T P Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00213-022-06303-5","article-title":"Effect of four-week cannabidiol treatment on cognitive function: Secondary\n                    outcomes from a randomised clinical trial for the treatment of cannabis use\n                    disorder","volume":"240","author":"R Lees","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41398-023-02410-9","article-title":"Effects of cannabidiol on anandamide levels in individuals with cannabis use\n                    disorder: Findings from a randomised clinical trial for the treatment of\n                    cannabis use disorder","volume":"13","author":"DY-H Hua","year":"2023","journal-title":"Transl Psychiatry"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1590\/1516-4446-2020-1416","article-title":"Cannabidiol for the treatment of crack-cocaine craving: An exploratory\n                    double-blind study","volume":"43","author":"C de Meneses-Gaya","year":"2021","journal-title":"Braz J Psychiatry"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/add.15417","article-title":"Cannabidiol as a treatment for craving and relapse in individuals with cocaine\n                    use disorder: A randomized placebo-controlled trial","volume":"116","author":"V Mongeau-P\u00e9russe","year":"2021","journal-title":"Addiction"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"173376","DOI":"10.1016\/j.pbb.2022.173376","article-title":"Cannabidiol effects on cognition in individuals with cocaine use disorder:\n                    Exploratory results from a randomized controlled trial","volume":"216","author":"E Rizkallah","year":"2022","journal-title":"Pharmacol Biochem Behav"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/adm.0000000000000959","article-title":"Cannabidiol effect on anxiety symptoms and stress response in individuals with\n                    cocaine use disorder: Exploratory results from a randomized controlled\n                    trial","volume":"16","author":"V Mongeau-P\u00e9russe","year":"2022","journal-title":"J Addict Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary\n                    findings","volume":"38","author":"CJ A Morgan","year":"2013","journal-title":"Addict Behav"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1111\/add.14243","article-title":"Cannabidiol reverses attentional bias to cigarette cues in a human experimental\n                    model of tobacco withdrawal","volume":"113","author":"C Hindocha","year":"2018","journal-title":"Addiction"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in\n                    drug-abstinent individuals with heroin use disorder: A double-blind randomized\n                    placebo-controlled Trial","volume":"176","author":"Y L Hurd","year":"2019","journal-title":"Am J Psychiatry"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"114840","DOI":"10.1016\/j.psychres.2022.114840","article-title":"An evidence-based approach to psychopharmacology for posttraumatic stress\n                    disorder (PTSD) - 2022 update","volume":"317","author":"L A Bajor","year":"2022","journal-title":"Psychiatry Res"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrn4036","article-title":"The endocannabinoid system in guarding against fear, anxiety and stress","volume":"16","author":"B Lutz","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejphar.2018.07.039","article-title":"Endocannabinoid system, stress and HPA axis","volume":"834","author":"V Micale","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00406-013-0470-8","article-title":"Fatty acid ethanolamide levels are altered in borderline personality and complex\n                    posttraumatic stress disorders","volume":"264","author":"C Schaefer","year":"2014","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e62741","DOI":"10.1371\/journal.pone.0062741","article-title":"Plasma concentrations of endocannabinoids and related primary fatty acid amides\n                    in patients with post-traumatic stress disorder","volume":"8","author":"D Hauer","year":"2013","journal-title":"PLoS ONE"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.psyneuen.2016.02.010","article-title":"Endocannabinoid concentrations in hair are associated with PTSD symptom\n                    severity","volume":"67","author":"S Wilker","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/mp.2013.61","article-title":"Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress\n                    disorder: A positron emission tomography study","volume":"18","author":"A Neumeister","year":"2013","journal-title":"Mol Psychiatr"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00213-021-05823-w","article-title":"Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in\n                    healthy adults: A randomized crossover study","volume":"238","author":"T C Spinella","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/bf00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by delta 9-THC\n                    in normal subjects","volume":"76","author":"A W Zuardi","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","article-title":"Effects of ipsapirone and cannabidiol on human experimental anxiety","volume":"7","author":"A W Zuardi","year":"1993","journal-title":"J Psychopharmacol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated\n                    public speaking test","volume":"41","author":"I M Linares","year":"2018","journal-title":"Braz J Psychiatry"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.npp.1300340","article-title":"Effects of cannabidiol (CBD) on regional cerebral blood flow","volume":"29","author":"J A de S Crippa","year":"2004","journal-title":"Neuropsychopharmacol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural\n                    activation during emotional processing","volume":"66","author":"P Fusar-Poli","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1017\/s1461145709990617","article-title":"Modulation of effective connectivity during emotional processing by delta\n                    9-tetrahydrocannabinol and cannabidiol","volume":"13","author":"P Fusar-Poli","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00213-022-06070-3","article-title":"The acute effects of cannabidiol on emotional processing and anxiety: A\n                    neurocognitive imaging study","volume":"239","author":"MA P Bloomfield","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose,\n                    multiple dose, and food effect trial of the safety, tolerability and\n                    pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"L Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.16093","article-title":"Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients\n                    with refractory epilepsy","volume":"60","author":"A K Birnbaum","year":"2019","journal-title":"Epilepsia"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/epi.16419","article-title":"A phase 1, randomized, pharmacokinetic trial of the effect of different meal\n                    compositions, whole milk, and alcohol on cannabidiol exposure and safety in\n                    healthy subjects","volume":"61","author":"J Crockett","year":"2020","journal-title":"Epilepsia"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/jcp.0000000000001691","article-title":"Interactive effects of ayahuasca and cannabidiol in social cognition in healthy\n                    volunteers: A pilot, proof-of-concept, feasibility, randomized-controlled\n                    trial","volume":"43","author":"G N Rossi","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0269881117737400","article-title":"The effects of cannabidiol on persecutory ideation and anxiety in a high trait\n                    paranoid group","volume":"32","author":"H Hundal","year":"2018","journal-title":"J Psychopharmacol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","article-title":"Cannabidiol enhances consolidation of explicit fear extinction in humans","volume":"226","author":"R K Das","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social\n                    anxiety disorder: A preliminary report","volume":"25","author":"JA S Crippa","year":"2011","journal-title":"J Psychopharmacol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in\n                    treatment-na\u00efve social phobia patients","volume":"36","author":"M M Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic effects of repeated cannabidiol treatment in teenagers with social\n                    anxiety disorders","volume":"10","author":"N Masataka","year":"2019","journal-title":"Front Psychol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euroneuro.2022.04.003","article-title":"Cannabidiol enhancement of exposure therapy in treatment refractory patients\n                    with social anxiety disorder and panic disorder with agoraphobia: A randomised\n                    controlled trial","volume":"59","author":"C M Kwee","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.21m14130","article-title":"Cannabidiol for treatment-resistant anxiety disorders in young people: An\n                    open-label trial","volume":"83","author":"M Berger","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1089\/acm.2018.0437","article-title":"Cannabidiol in the treatment of post-traumatic stress disorder: A case\n                    series","volume":"25","author":"L Elms","year":"2019","journal-title":"J Altern Complement Med"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-021-06043-y","article-title":"Effects of cannabidiol on symptoms induced by the recall of traumatic events in\n                    patients with posttraumatic stress disorder","volume":"239","author":"L M Bolsoni","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1590\/1516-4446-2021-2317","article-title":"The anxiolytic effect of cannabidiol depends on the nature of the trauma when\n                    patients with post-traumatic stress disorder recall their trigger event","volume":"44","author":"L M Bolsoni","year":"2022","journal-title":"Braz J Psychiatry"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"k1674","DOI":"10.1136\/bmj.k1674","article-title":"Autism spectrum disorder: advances in diagnosis and evaluation","volume":"361","author":"L Zwaigenbaum","year":"2018","journal-title":"BMJ"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4103\/1673-5374.360163","article-title":"Recent advancements in noninvasive brain modulation for individuals with autism\n                    spectrum disorder","volume":"18","author":"J R Griff","year":"2022","journal-title":"Neural Regen Res"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum\n                    disorder","volume":"9","author":"D S Karhson","year":"2018","journal-title":"Mol Autism"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","article-title":"Effects of cannabidiol on brain excitation and inhibition systems; a randomised\n                    placebo-controlled single dose trial during magnetic resonance spectroscopy in\n                    adults with and without autism spectrum disorder","volume":"44","author":"C M Pretzsch","year":"2019","journal-title":"Neuropsychopharmacol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/0269881119858306","article-title":"The effect of cannabidiol (CBD) on low-frequency activity and functional\n                    connectivity in the brain of adults with and without autism spectrum disorder\n                    (ASD)","volume":"33","author":"C M Pretzsch","year":"2019","journal-title":"J Psychopharmacol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/yco.0000000000000562","article-title":"Cannabinoids and the endocannabinoid system in anxiety, depression, and\n                    dysregulation of emotion in humans","volume":"33","author":"V L Chadwick","year":"2020","journal-title":"Curr Opin Psychiatry"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/adb.12495","article-title":"Cannabidiol reduces ethanol consumption, motivation and relapse in mice","volume":"23","author":"A Viudez-Mart\u00ednez","year":"2018","journal-title":"Addict Biol"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"e12765","DOI":"10.1111\/adb.12765","article-title":"Gender differences in the effects of cannabidiol on ethanol binge drinking in\n                    mice","volume":"25","author":"A Viudez-Mart\u00ednez","year":"2020","journal-title":"Addict Biol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1111\/bph.14380","article-title":"Effects of cannabidiol plus naltrexone on motivation and ethanol\n                    consumption","volume":"175","author":"A Viudez-Mart\u00ednez","year":"2018","journal-title":"Br J Pharmacol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","article-title":"Unique treatment potential of cannabidiol for the prevention of relapse to drug\n                    use: Preclinical proof of principle","volume":"43","author":"G Gonzalez-Cuevas","year":"2018","journal-title":"Neuropsychopharmacol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-022-06196-4","article-title":"Cannabidiol for the treatment of autism spectrum disorder: Hope or hype","volume":"239","author":"JF C Pedrazzi","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jchemneu.2019.04.006","article-title":"Emerging evidence for the antidepressant effect of cannabidiol and the\n                    underlying molecular mechanisms","volume":"98","author":"G P Silote","year":"2019","journal-title":"J Chem Neuroanat"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3390\/pharmaceutics14122598","article-title":"Adverse effects of oral cannabidiol: An updated systematic review of randomized\n                    controlled trials (2020\u20132022)","volume":"14","author":"JD R Souza","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2174\/1570159x17666190603171901","article-title":"Cannabidiol adverse effects and toxicity","volume":"17","author":"M A Huestis","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-642-25761-2_7","article-title":"Medical needs in the treatment of psychotic disorders","author":"F M Leweke","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/wps.20941","article-title":"The efficacy of psychotherapies and pharmacotherapies for mental disorders in\n                    adults: An umbrella review and meta-analytic evaluation of recent\n                    meta-analyses","volume":"21","author":"F Leichsenring","year":"2022","journal-title":"World Psychiatry"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: State of the art and new directions","volume":"27","author":"O D Howes","year":"2022","journal-title":"Mol Psychiatry"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"bvac120","DOI":"10.1210\/jendso\/bvac120","article-title":"Endocannabinoid system in the neuroendocrine response to\n                    lipopolysaccharide-induced immune challenge","volume":"6","author":"A D Laurentiis","year":"2022","journal-title":"J Endocr Soc"},{"key":"ref114","first-page":"61","article-title":"The endocannabinoid system role in the pathogenesis of obesity and\n                    depression","volume":"39","author":"A Zdanowicz","year":"2015","journal-title":"Polski Merkur L\u00e9k\u202f: organ Polskiego Towar\n                    L\u00e9k"},{"key":"ref115","first-page":"183","article-title":"A new face of endocannabinoids in pharmacotherapy. Part II: Role of\n                    endocannabinoids in inflammation-derived cardiovaascular diseases","volume":"65","author":"M Zubrzycki","year":"2013","journal-title":"J Physiol Pharmacol\u202f: Off J Pol Physiol Soc"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: Signaling and function in\n                    the central nervous system","volume":"19","author":"S Zou","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are\n                    inversely correlated with psychotic symptoms","volume":"29","author":"A Giuffrida","year":"2004","journal-title":"Neuropsychopharmacol"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3389\/fpsyt.2020.00628","article-title":"Peripheral endogenous cannabinoid levels are increased in schizophrenia patients\n                    evaluated in a psychiatric emergency setting","volume":"11","author":"S Potvin","year":"2020","journal-title":"Front Psychiatry"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms\n                    in drug-free patients with schizophrenia","volume":"79","author":"J Ceccarini","year":"2013","journal-title":"Neuroimage"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of\n                    psychosis","volume":"194","author":"D Koethe","year":"2009","journal-title":"Br J Psychiatry"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2228-6118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T01:49:38Z","timestamp":1771033778000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2228-6118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":120,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,5,7]]},"published-print":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2228-6118","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}